Company Filing History:
1 out of 1,745 
1 out of 38 
1 out of 6 Years Active: 2022
Title: **Innovator Spotlight: Pascal Trouve**
Introduction
Pascal Trouve, based in Brest, France, is an influential inventor in the field of pharmaceutical science. With a focus on improving treatments for diseases associated with cystic fibrosis, Trouve has made significant contributions through his research and patents.
Latest Patents
Pascal Trouve holds a patent titled "Methods and pharmaceutical compositions for the treatment of diseases associated with reduced CFTR function." This invention highlights the role of Activating Transcription Factor 6 (ATF6) in the repression of cystic fibrosis transmembrane conductance regulator (CFTR). By utilizing a site-1 protease (S1P) inhibitor, such as PF-429242, Trouve and his research team demonstrated a partial restoration of F508del-CFTR's membrane localization and functionality. The patent outlines a method for treating diseases related to reduced CFTR function by administering a therapeutically effective amount of an S1P inhibitor, providing hope for those affected by such conditions.
Career Highlights
Throughout his career, Pascal Trouve has worked in esteemed institutions, notably the Institut National de la Santé et de la Recherche Médicale and the Université de Bretagne Occidentale. His dedication to advancing medical science has positioned him as a notable figure in the field of research.
Collaborations
Trouve has collaborated with reputable colleagues, including Claude Ferec and Mathieu Kerbiriou. Their joint efforts have greatly enhanced the understanding of CFTR function and its potential therapeutic targets.
Conclusion
Pascal Trouve’s work embodies the spirit of innovation and dedication within the medical research community. His contributions, particularly in the area of cystic fibrosis treatment, are paving the way for advancements that could significantly improve the lives of many individuals suffering from related diseases.